Free shipping on all orders over $ 500

JI-101

Cat. No. M8949

All AbMole products are for research use only, cannot be used for human consumption.

JI-101 Structure
Size Price Availability Quantity
5mg USD 85  USD85 In stock
10mg USD 140  USD140 In stock
25mg USD 280  USD280 In stock
50mg USD 480  USD480 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

JI-101 is an orally available multi-kinase inhibitor of VEGFR2,PDGFRβ and EphB4 with potent anti-cancer activity. JI-101 is rapidly absorbed, reaching Cmax within 2 h. The t1/2 of JI-101 with intravenous and oral route is found to be 1.75±0.79 and 2.66±0.13 h, respectively. The Cl and Vd by intravenous route for JI-101 are found to be 13.0±2.62 mL/min/kg and 2.11±1.42 L/kg, respectively. The tissue distribution of JI-101 is extensive with rapid and preferred uptake into lung tissue.

Protocol (for reference only)
Cell Experiment
Cell lines
Preparation method
Concentrations
Incubation time
Animal Experiment
Animal models male S.D. rats
Formulation
Dosages 3 and 30 mg/kg
Administration i. v. (via tail vein) and oral dose (by gavage)
Chemical Information
Molecular Weight 466.33
Formula C22H20BrN5O2
CAS Number 900573-88-8
Solubility (25°C) DMSO 10 mM
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Gurav SD, et al. Arzneimittelforschung. Pharmacokinetics, tissue distribution and identification of putative metabolites of JI-101 - a novel triple kinase inhibitor in rats.

[2] Sharma S, et al. Biomed Chromatogr. Highly sensitive method for the determination of JI-101, a multi-kinase inhibitor in human plasma and urine by LC-MS/MS-ESI: method validation and application to a clinical pharmacokinetic study.

Related VEGFR/PDGFR Products
Conbercept

Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc.

SU5208 

SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).

VEGFR-IN-1 

VEGFR-IN-1 is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively.

(Z)-Orantinib

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively.

(Rac)-SAR131675 

(Rac)-SAR131675 is the racemate of SAR131675.

  Catalog
Abmole Inhibitor Catalog




Keywords: JI-101 supplier, VEGFR/PDGFR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.